Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Candel Therapeutics is committed to improving treatments for patients suffering from autoimmune and inflammatory diseases by identifying and developing innovative, cutting-edge therapeutics that address unmet medical needs.

Candel Therapeutics' vision is to offer the best cutting-edge treatments for diseases associated with inflammation and autoimmune disorders to improve the lives of those affected.

Candel Therapeutics has been the recipient of numerous awards and recognitions, including the prestigious Innovation Prize, presented by Frost & Sullivan in 2012. The award recognizes the company’s ability to develop innovative, proven treatments for difficult-to-treat diseases such as autoimmune disorders and inflammatory conditions.